EHTH vs EBS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EBS Captures Institutional Edge (2โ2 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Emergent Biosolutions, Inc. (EBS) driven by superior Momentum & Technical, Options & Structure while EHTH counters with relative strength in Valuation, Growth & Margin. Fundamentally, EHTH trades at 0.2x Forward P/E with 11.9% operating margin (-60.5% YoY revenue) versus EBS at 20.0x Forward P/E and 5.8% operating margin (-52.4% YoY). In options structure, EHTH sits in UNCLASSIFIED (56th %ile IV; Dealer Gamma Walls on Pro) against EBS sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EHTH | EBS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $13.4M | $297.7M | Larger Scale | EBS |
| Trailing P/E Ratio Valuation | 0.2x | 20.0x | Lower Multiple | EHTH |
| Forward P/E Ratio Valuation | 0.2x | 20.0x | Lower Multiple | EHTH |
| Revenue Growth (YoY) Growth | -60.5% | -52.4% | Higher Growth | EBS |
| Operating Margin (TTM) Profitability | 11.9% | 5.8% | Higher Margin | EHTH |
| Net Profit Margin Profitability | 4.9% | -40.2% | Higher Margin | EHTH |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -58.2% | Higher ROE | EHTH |
| 52-Week Range Position Momentum | 0% ($0โ$5) | 13% ($4โ$14) | Stronger Trend | EBS |
| Beta / 30D Volatility Risk Regime | 1.61ฮฒ ยท 117% Vol | 0.81ฮฒ ยท 49% Vol | Lower Realized Risk | EBS |
| Unified Institutional Score Composite Signal | 40.8 / 100 (SELL) | 54.3 / 100 (HOLD) | Higher Composite | EBS |